^
Association details:
| Biomarker: | BCR-ABL1 Y253H |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Excerpt:
A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML, and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-positive ALL….Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib...Supplemental Table 4 - Summary of Dasatinib Treatment Responses and Bcr/Abl Genotype in Advanced Phase Patients.
DOI:
10.1056/NEJMoa055229
Trial ID:
